Analytical Data
-
Gene name
ASNA1
- Application
-
Alternative Names
Arsenical pump-driving ATPase
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O43681
-
Expression Region
2-348aa
-
Molecular Weight
54.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ASNA1, or Arylsulfatase A, is an essential enzyme involved in the degradation of sulfatides, which are important for the integrity of myelin sheaths in the nervous system. Mutations in the ASNA1 gene are associated with a rare genetic disorder known as metachromatic leukodystrophy (MLD), leading to severe neurological impairment due to the accumulation of sulfatides. Researchers focus on the recombinant expression and purification of ASNA1 to better understand its structural and functional properties, paving the way for potential therapeutic interventions. The production of ASNA1 as a recombinant protein allows scientists to investigate its enzymatic mechanisms, develop enzyme replacement therapies, and explore its role in cellular processes. This research is significant not only for elucidating the biochemical pathways involved in MLD but also for advancing our understanding of related neurological disorders and aiding in the development of targeted treatment strategies. Through advancements in recombinant DNA technology and protein engineering, the detailed characterization of ASNA1 can unveil insights into its substrate specificity and regulatory mechanisms, fostering the discovery of novel approaches to mitigate the effects of genetic defects associated with this enzyme. Overall, the study of ASNA1 recombinant protein represents a crucial step toward improving patient outcomes in genetic conditions linked to enzyme deficiencies.
